For Q1 FY2026 ended March 31, 2026, MBX Biosciences reported no revenue and a net loss of $23.5 million, an increase of 152% year-over-year. Operating loss was $27.3 million, up 2.8% from the prior year. Diluted EPS was -$0.50, improving 29.6% year-over-year. Cash and cash equivalents stood at $45.2 million, with total equity of $437.8 million.
•Net loss widened to $23.5 million from $9.3 million in Q1 FY2025.
•Operating loss increased to $27.3 million from $26.5 million.
•Diluted EPS improved to -$0.50 from -$0.71.
•Cash position of $45.2 million and equity of $437.8 million.
Informational summary based on SEC XBRL figures · generated by deepseek-v4-flash. Not investment advice.
MBX Biosciences, Inc., a clinical-stage biopharmaceutical company focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders.
Its lead product candidate is Canvuparatide (MBX 2109), a parathyroid hormone peptide prodrug, which is in Phase 3 clinical trial for the treatment of chronic hypoparathyroidism.
The company is also developing Imapextide (MBX 1416), a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 2 clinical trial a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery.
Additionally, it is developing MBX 4291, a lead obesity product candidate, which is in investigational new drug-enabling studies for the treatment of obesity and co-morbidities. Founded in 2018, the company is based in Carmel, Indiana.
MBX Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing precision peptide therapies for endocrine and metabolic disorders. Its lead candidate, Canvuparatide (MBX 2109), is a parathyroid hormone peptide prodrug in Phase 3 trials for chronic hypoparathyroidism. The company also has Imapextide (MBX 1416), a long-acting GLP-1 receptor antagonist in Phase 2 for post-bariatric hypoglycemia, and MBX 4291, an obesity candidate in investigational new drug-enabling studies. Founded in 2018, MBX Biosciences is headquartered in Carmel, Indiana.
On which stock exchange is MBX Biosciences listed and what is its ticker symbol?
MBX Biosciences, Inc. is listed on the Nasdaq Global Select Market (NasdaqGS) under the ticker symbol MBX. Its shares are traded in U.S. dollars (USD), reflecting its primary listing in the United States. As a Nasdaq-listed company, MBX Biosciences is subject to the exchange's listing standards and reporting requirements, providing transparency for investors. The ticker MBX is used by investors to track the company's stock performance and market activity.
What sector and industry does MBX Biosciences belong to?
MBX Biosciences operates in the Healthcare sector, specifically within the Biotechnology industry. As a biotechnology company, it focuses on developing innovative therapies using biological processes and molecules. Its precision peptide therapies target endocrine and metabolic disorders, a specialized area within biotech. The company's clinical-stage pipeline includes candidates for hypoparathyroidism, post-bariatric hypoglycemia, and obesity, aligning with its biotech classification. This sector and industry designation helps investors understand the company's regulatory environment, research-driven nature, and potential for high-risk, high-reward drug development.
Where is MBX Biosciences headquartered and what markets does it serve?
MBX Biosciences is headquartered in Carmel, Indiana, United States. The company primarily serves the U.S. market, as indicated by its country and region classification. Its clinical trials for Canvuparatide, Imapextide, and MBX 4291 are likely conducted in the U.S., targeting patients with endocrine and metabolic disorders. While the company may explore global markets in the future, its current focus is on the United States. The Carmel location provides access to a skilled workforce and proximity to research institutions, supporting its biopharmaceutical development activities.
What are MBX Biosciences' main product candidates and their stages of development?
MBX Biosciences has three key product candidates. Canvuparatide (MBX 2109) is a parathyroid hormone peptide prodrug in Phase 3 clinical trials for chronic hypoparathyroidism, a condition where the body produces insufficient parathyroid hormone. Imapextide (MBX 1416) is a long-acting GLP-1 receptor antagonist in Phase 2 for post-bariatric hypoglycemia, a complication of bariatric surgery. MBX 4291 is a lead obesity candidate undergoing investigational new drug-enabling studies for obesity and related comorbidities. These candidates represent the company's pipeline targeting significant unmet medical needs in endocrine and metabolic disorders.